Skip to main content
. 2020 Aug 14;10:13831. doi: 10.1038/s41598-020-70764-x

Figure 3.

Figure 3

Drug interaction between 116-9e (DNAJA1 inhibitor) and selected hits. LNCaP cells were treated with different concentrations of cabozantinib (A), clofarabine (B), vinblastine (C), idarubicin (D), omacetaxine (E) and sorafenib (F) with or without 116-9e for 72 h in RPMI-1640 medium containing 10% FBS. Each point is the mean ± SD for three independent experiments. Growth inhibition was determined using Cell Titer-Glo assay. Combination Index (CI, measure of drug synergy) was determined using Chou-Talalay method via Compusyn software. CI values are as follows: < 0.1 (very strongly synergistic), 0.1–0.3 (strongly synergistic), < 0.9 (synergistic), 0.9–1.1 (additive), 1.1–3.3 (antagonistic), 3.3–10 (strongly antagonistic), > 10 (very strongly antagonistic).